0001562180-23-005323.txt : 20230620 0001562180-23-005323.hdr.sgml : 20230620 20230620110254 ACCESSION NUMBER: 0001562180-23-005323 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230616 FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mosca Alison CENTRAL INDEX KEY: 0001835537 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39834 FILM NUMBER: 231023921 MAIL ADDRESS: STREET 1: 26 PATRIOT PLACE, SUITE 301 CITY: FOXBORO STATE: MA ZIP: 02035 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clene Inc. CENTRAL INDEX KEY: 0001822791 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 852828339 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 BUSINESS PHONE: 801-676-9695 MAIL ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 FORMER COMPANY: FORMER CONFORMED NAME: Chelsea Worldwide Inc. DATE OF NAME CHANGE: 20200827 4 1 primarydocument.xml PRIMARY DOCUMENT X0407 4 2023-06-16 false 0001822791 Clene Inc. CLNN 0001835537 Mosca Alison 6550 SOUTH MILLROCK DRIVE SUITE G50 SALT LAKE CITY UT 84121 true false false false false Common Stock 2023-06-16 4 P false 2394375.00 0.80 A 3238375.00 I By LLC Common Stock 39476.00 D Common Stock 3006670.00 I By LP Common Stock 1459945.00 I By trust Warrants (Right to buy) 1.50 2023-06-16 4 A false 2394375.00 A 2023-06-16 Common Stock 2394375.00 2394375.00 D Warrants (Right to buy) 1.10 2023-06-16 4 A false 2394375.00 A 2023-06-16 Common Stock 2394375.00 2394375.00 D The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. Please note that Kensington Clene 2021, LLC had been incorrectly referred to in prior form 4s for Ms. Mosca as Kensington Clene, LLC; there is no such legal entity, only Kensington Clene 2021, LLC. The securities are owned by the Kensington Investments, L.P. Ms. Mosca is the chief executive officer of Kensington Investments, L.P. The shares owned by the Kensington Investments, L.P. may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Investments, L.P. , for which she does not have a pecuniary or profits interest. The securities are owned by the Robert C. Gay 1998 Family Trust. Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust. The shares owned by the Robert C. Gay 1998 Family Trust may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust. The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. Kensington Clene 2021, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 2,394,375 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration approval of a New Drug Application from Clene Inc. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. Kensington Clene 2021, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 2,394,375 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. /s/ Jerry Miraglia POA 2023-06-20